Video
Dr. Motzer on where pembrolizumab/lenvatinib fits in advanced RCC treatment paradigm
Author(s):
Video Player is loading.
In an interview during the 2021 ASCO Annual Meeting Robert J. Motzer, MD, discussed where the combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) fits into the treatment paradigm for advanced renal cell carcinoma (RCC), based on findings from the phase 3 CLEAR trial. In the study the combination reduced the risk of death by 34% versus sunitinib (Sutent) in the frontline RCC setting. Motzer is the Kidney Cancer Section Head, Genitourinary Oncology Service; and Jack and Dorothy Byrne Chair in Clinical Oncology at Memorial Sloan Kettering Cancer Center.
Related Videos
5 key trial insights from AUA 2025
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Margaret Knoedler, MD, on Ho:YAG vs thulium fiber laser for ureteroscopy
John Gore, MD, on radical cystectomy vs bladder-sparing therapy for NMIBC
Related Content
